SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India

12 May 2020 Evaluate
Glenmark Pharmaceuticals has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India’s drug regulator DCGI in late April. Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India.

Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co., Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government & private hospitals in India are being enrolled for the study. Glenmark estimates study completion by July/August 2020. 

Glenmark has successfully developed the API and the formulations for the product through its inhouse R&D team. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections.  The molecule if commercialized, will be marketed under the brand name ‘FabiFlu’ in India.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2249.00 1.10 (0.05%)
20-Apr-2026 09:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.60
Dr. Reddys Lab 1232.65
Cipla 1242.10
Zydus Lifesciences 944.25
Lupin 2328.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×